Product Name: Herpes Zoster Vaccine, Live
Approval No.: S20233097
Extend Age Group
According to American CDC, 30% people will develop herpes zoster, the positive rate of VZV IgG antibody increases with age, the positive rate of VZV IgG antibody is more than 98% for people at or above age of 40 years which means more potential people to develop herpes zoster with older people. A 20-year data review from the Asia-Pacific region shows that the incidence of herpes zoster over 40 years old increases. BCHT’s Herpes Zoster Vaccine, Live is indicated for adults at or above age of 40 years which fills the gap of herpes zoster vaccination for people aged 40 to 50 and benefits more people.
Early Inoculation, Early Benefit
At present, the incidence of herpes zoster tends to be younger, after 40 years old, VZV- specific cellular immune function decreases significantly, the younger to vaccinate, the stronger immune response, so early inoculation, early benefit.
One Dose Immunization, Safe and Secure
BCHT’s Herpes Zoster Vaccine, Live is one dose immunization compared with the imported vaccines with two doses immunization, it is more convenient and has a good economic benefit cost; For safety, the incidence of common adverse reactions is less than 10% including fever etc., vaccination is more reassuring.